{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "An association of companies that make nonprescription drugs said today that its members had no intention of following the lead of Johnson & Johnson in withdrawing capsules from the market. ''It simply is not the solution,'' said John T. Walden, the spokesman for the pharmaceutical group, the Proprietary Association. Mr. Walden did not criticize Johnson & Johnson, which announced on Monday that it would no longer market its Tylenol or other nonprescription drugs in capsules. The company said it acted to prevent the kind of tampering that recently killed a Westchester County woman who took cyanide-laced capsules of Extra-Strength Tylenol.", "headline": {"main": "MANY DRUG MAKERS PLAN TO CONTINUE CAPSULE USE"}, "abstract": null, "print_page": "1", "word_count": 521, "_id": "4fd160d68eb7c8105d64ad19", "snippet": "An association of companies that make nonprescription drugs said today that its members had no intention of following the lead of Johnson & Johnson in withdrawing capsules from the market.   ''It simply is not the solution,'' said John T. Walden, the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1986/02/19/us/many-drug-makers-plan-to-continue-capsule-use.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FEDERAL BUREAU OF INVESTIGATION"}, {"name": "organizations", "value": "JOHNSON & JOHNSON INC"}, {"name": "organizations", "value": "PROPRIETARY ASSN"}, {"name": "organizations", "value": "MCNEIL CONSUMER PRODUCTS CO"}, {"name": "subject", "value": "TYLENOL (DRUG)"}, {"name": "subject", "value": "POISONING AND POISONS"}, {"name": "subject", "value": "CYANIDE"}, {"name": "subject", "value": "CONTAINERS AND PACKAGING"}, {"name": "subject", "value": "POTASSIUM CYANIDE"}, {"name": "subject", "value": "PAIN-RELIEVING DRUGS"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "DRUGS AND DRUG TRADE"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Irvin", "lastname": "MOLOTSKY"}, {"organization": "", "role": "reported", "rank": 2}], "original": "By IRVIN MOLOTSKY, Special to the New York Times"}, "document_type": "article", "pub_date": "1986-02-19T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Financial Desk", "lead_paragraph": "An already competitive battle for the huge market for pain relievers can only become more complicated after the latest Tylenol poisoning episode. Since the middle of 1984, a new type of non-prescription analgesic, ibuprofen, has been making major inroads, putting pressure on better-established products. The ibuprofen pain relievers - sold under the brand names Advil and Nuprin - have captured 9 percent of the $1.7 billion market. That is less, however, than the 15 to 20 percent market share some experts had expected when the product was introduced. But many industry experts predict that the drug's share will continue to grow, further squeezing aspirin and acetaminophen products, such as Tylenol. ''The companies are now beginning to gain the market shares anticipated after a slow start,'' said Ronald M. Nordmann, an analyst at Paine Webber.", "headline": {"main": "ANALGESIC MAKERS IN A BATTLE"}, "abstract": null, "print_page": "1", "word_count": 969, "_id": "4fd160d48eb7c8105d64abf4", "snippet": "An already competitive battle for the huge market for pain relievers can only become more complicated after the latest Tylenol poisoning episode.   Since the middle of 1984, a new type of non-prescription analgesic, ibuprofen, has been making major...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1986/02/18/business/analgesic-makers-in-a-battle.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "FORECASTS"}, {"name": "subject", "value": "PAIN-RELIEVING DRUGS"}, {"name": "subject", "value": "NEW MODELS, DESIGN AND PRODUCTS"}, {"name": "subject", "value": "IBUPROFEN (DRUG)"}], "byline": null, "document_type": "article", "pub_date": "1986-02-18T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "The condition of Roy M. Cohn, who is suffering from liver cancer, remains ''very precarious'' after four months of treatment with ''a new, experimental drug,'' his physician said in an affidavit filed last week The physician, Dr. Bijan Safai of the Memorial Sloan-Kettering Cancer Center, said in the affidavit that the lawyer appeared to have made progress in ''important areas,'' but that it was ''too early to determine what overall effect this drug is having on the disease, which is threatening Mr. Cohn's life.'' The affidavit, dated Feb. 10, was submitted by Mr. Cohn's lawyers in the Appellate Division of State Supreme Court in Manhattan, where Mr. Cohn is fighting disbarment proceedings. In a telephone conversation last week, Dr. Safai refused to comment on the affidavits or on Mr. Cohn's condition.", "headline": {"main": "Cohn's Health Called 'Precarious' by Doctor"}, "abstract": null, "print_page": "2", "word_count": 131, "_id": "4fd15fd68eb7c8105d648f62", "snippet": "The condition of Roy M. Cohn, who is suffering from liver cancer, remains ''very precarious'' after four months of treatment with ''a new, experimental drug,'' his physician said in an affidavit filed last week The physician, Dr. Bijan Safai of the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1986/02/18/nyregion/cohn-s-health-called-precarious-by-doctor.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "SAFAI, BIJAN"}, {"name": "persons", "value": "COHN, ROY M"}, {"name": "organizations", "value": "MEMORIAL SLOAN-KETTERING CANCER CENTER"}, {"name": "subject", "value": "LAWYERS"}, {"name": "subject", "value": "HEALTH, PERSONAL"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "DRUGS AND DRUG TRADE"}, {"name": "subject", "value": "LEGAL PROFESSION"}], "byline": null, "document_type": "article", "pub_date": "1986-02-18T00:00:00Z", "section_name": "Health; New York and Region"}], "meta": {"hits": 3, "offset": 0, "time": 40}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}